Nurix Therapeutics, Inc. Stock Price, News & Analysis

Nurix Therapeutics (NASDAQ: NRIX) reported Phase 1a data for NX-1607, a first-in-class oral CBL-B inhibitor, presented at ESMO 2025.

In 82 treated patients (71 evaluable as of July 26, 2025) across 5–80 mg total daily doses, NX-1607 showed dose-dependent exposure, peripheral immune activation, reductions in tumor biomarkers (PSA, CEA), tumor shrinkage, long-term stable disease, and a confirmed partial response in a patient with MSS colorectal cancer. The disease control rate was 49.3%. Six patients had immune-related adverse events; most treatment-emergent adverse events were Grade ≤2. Data support initiating expansion cohorts at the two highest doses as monotherapy or in combination for advanced solid tumors.

Nurix Therapeutics (Nasdaq: NRIX) reported Q3 2025 results and program updates on Oct 9, 2025. The company plans to initiate pivotal studies for bexobrutideg in relapsed/refractory CLL in H2/Q4 2025, including a single‑arm path for potential accelerated approval and a randomized Phase 3 confirmatory trial. Encore Phase 1 data showed ORR 80.9% in CLL and ORR 84.2% in WM. Preclinical data for IRAK4 degrader GS-6791 were presented. Cash and marketable securities were $428.8M as of Aug 31, 2025.

Nurix Therapeutics (Nasdaq: NRIX) presented preclinical data for GS-6791, a novel IRAK4 protein degrader, at the EADV Congress in Paris. The data demonstrates the drug's effectiveness in treating inflammatory diseases through potent IRAK4 degradation and inhibition of IL-1 and IL-36 signaling pathways.

Key findings show that GS-6791 achieved near-complete IRAK4 knockdown in human blood and keratinocytes, reduced proinflammatory cytokines, and improved barrier function in dermatitis models. The compound, developed in collaboration with Gilead Sciences, is currently in a Phase 1 clinical trial evaluating its safety and tolerability in healthy volunteers.

Nurix Therapeutics (Nasdaq: NRIX), a clinical-stage biopharmaceutical company specializing in targeted protein degradation medicines, has announced its participation in multiple investor conferences during September 2025.

The company's leadership team, including CEO Arthur T. Sands, CFO Hans van Houte, CCO John Northcott, and CBO Jason Kantor, will attend five major healthcare conferences: Wells Fargo, H.C. Wainwright, RW Baird, Morgan Stanley, and Stifel Virtual Immunology Forum. All presentations will be webcast live and available for 30 days through Nurix's website.

Nurix Therapeutics (Nasdaq: NRIX) reported significant progress in Q2 2025, highlighted by positive clinical developments and strategic collaborations. The company presented updated data for bexobrutideg (NX-5948), showing an impressive 80.9% objective response rate in r/r CLL patients. Nurix secured a $15M license fee from Sanofi's STAT6 collaboration extension and received FDA clearance for IRAK4 degrader GS-6791/NX-0479.

Financial highlights include Q2 2025 revenue of $44.1M, up from $12.1M year-over-year, and a strong cash position of $485.8M. R&D expenses increased to $78.1M from $48.9M, while net loss improved to $43.5M ($0.52 per share) compared to $44.5M ($0.71 per share) in Q2 2024.

Nurix Therapeutics (Nasdaq: NRIX) announced that its drug bexobrutideg (NX-5948) has received Orphan Drug Designation from the European Medicines Agency for treating lymphoplasmacytic lymphoma, also known as Waldenström macroglobulinemia (WM).

The designation provides significant benefits including 10 years of market exclusivity in the EU upon approval, protocol assistance, and reduced regulatory fees. Bexobrutideg, an oral BTK degrader, is currently in Phase 1a/b clinical trials for relapsed or refractory B-cell malignancies.

The drug has already received multiple regulatory designations, including FDA Fast Track for WM and CLL/SLL treatment, and EMA PRIME designation for CLL/SLL treatment, demonstrating strong regulatory momentum.

Nurix Therapeutics (NRIX), a clinical-stage biopharmaceutical company specializing in targeted protein degradation medicines, has granted inducement awards to 17 new employees on June 10, 2025. The awards include stock options for 97,400 shares with an exercise price of $12.79 per share and restricted stock units (RSUs) for 66,750 shares. The stock options will vest over four years, with 25% vesting after one year and the remainder vesting monthly. RSUs will also vest over four years, with 25% vesting after one year and the remainder vesting quarterly. The grants were made under Nurix's 2024 Equity Inducement Plan and approved by the Compensation Committee in compliance with Nasdaq Listing Rule 5635(c)(4).

Nurix Therapeutics announced positive clinical data for bexobrutideg (NX-5948) in treating relapsed/refractory CLL and WM patients. The Phase 1a/b trial showed impressive results with an 80.9% overall response rate in CLL patients and 84.2% in WM patients. The drug demonstrated durable responses, including a complete response in one CLL patient after two years of treatment. The study included heavily pretreated patients with a median of four prior therapies for CLL and three for WM. Bexobrutideg was well-tolerated across all doses, with no new safety concerns and notably no new onset atrial fibrillation. The company plans to initiate pivotal trials in 2025, positioning bexobrutideg as a potential breakthrough treatment for patients with limited therapeutic options.

Nurix Therapeutics (NRIX) announced a webcast conference call scheduled for June 12, 2025, at 8:00 a.m. ET to discuss new data from their ongoing Phase 1 clinical trial of bexobrutideg (NX-5948). The data will be presented at the European Hematology Association Congress in Milan. Two poster presentations will showcase the drug's performance: one focusing on its efficacy in relapsed refractory CLL, presented by Dr. Talha Munir, and another highlighting its clinical activity and safety in Waldenström macroglobulinemia patients, presented by Dr. Dima El-Sharkawi. The webcast will be accessible through Nurix's website, with dial-in options available for U.S. and international participants. A replay will be archived for approximately 30 days after the event.